Navigation Links
S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/2/2009

of pharmacodynamic (PD) biomarker assays for SB1518 will be presented in a poster, demonstrating PD target efficacy of SB1518 in animal tumor models, as well as, in patients in ongoing Phase 1 clinical studies for advanced leukemias, myeloproliferative diseases and lymphoma. The fourth poster will highlight the effects of SB1518 on ex vivo expanded polycythemia vera (PV) erythroid progenitors which correlate with clinical observations.

Poster No.: 3905, Time: 6-8 p.m. CST, Monday, Dec. 7, 2009, Location: Hall E (Ernest N. Morial Convention Center)

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis

SB1518, which is a potent ATP-competitive inhibitor of JAK2 (IC50=22nM), JAK2V617F mutant (IC50=19nM), FLT3 (IC50=22nM) and its mutant D835Y (IC50=6nM), is being tested to determine its safety, tolerability and PK/PD profile when administered orally once daily continuously in 28-day cycles. SB1518 was well tolerated at doses up to 500 mg daily in patients with advanced myelofibrosis (MF) and acute myelogenous leukemias (AML), and shows clinical activity in MF patients with splenomegaly.

Oral Presentation Abstract No.: 588, Time: 4 p.m. CST, Monday, Dec. 7, 2009, Location: Room R02-R05

Phase 1 Study of the Novel Oral JAK2 Inhibitor SB1518 in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity

A Phase 1 dose escalating study of the novel JAK2 small molecule inhibitor SB1518 is being conducted in patients with relapsed Hodgkin (HL) and non-Hodgkin lymphomas (NHL). The primary objectives are to examine the safety and efficacy of SB1518 in this patient population. Patients are treated at four dose levels (100 mg, 200 mg, 300 mg, and 400 mg) orally daily without interruption.
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. S*BIO Completes US$26 Million Equity Financing
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
5. Novel Technology Breaks Through Cancer Pain
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
9. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
10. NIST team develops novel method for nanostructured polymer thin films
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in ... the PandaPLUS 2000, which is ideal for new applications ... cell disruption . This compact laboratory homogenizer is the ... food, food additives and ingredients as well as for ...
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... development places National Stem Cell in the sector for Anti-aging, ... and one of the ... Today, MOUNTAINSIDE, N.J., Oct. 25 National Stem,Cell Holding, ... is currently in final stage negotiations to exclusively license one ...
... Mass., Oct. 25 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... a,conference call at 8:00 a.m. ET on Thursday, ... third-quarter 2007 financial and,operational results and upcoming activities. ... available on the webcast. Prior to the,conference call ...
... Glycominds Ltd., a,bio-diagnostics company specializing in glycan ... and cancer, announced today,entering into a research agreement ... cancer center to develop a new diagnostics blood ... to work with FCCC on this project," stated ...
Cached Biology Technology:National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications 2Millennium to Webcast Third-Quarter 2007 Financial and Operational Results 2Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests 2
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market ... it is important to upgrade biometric solutions to the ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for a ... for this $50 million capital project is part of a ... The medical education building will be located ... adjacent to 525@vine in Wake Forest Innovation Quarter. Construction will ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... -- Reseachers at The Ohio State University have ... an effective method for preserving the important genetic diversity ... geranium, are some of the most popular flowers the ... Society listed more than 3,000 varieties of geranium in ...
... -- Two common dietary molecules found in legumes ... effects of radiation, researchers from the University of ... both human skin cells and a skin cancer-prone ... the damaging radiation found in sunlight, the team ...
... scientists today announced the results of a systematic effort ... worlds leading cause of cancer deaths. Appearing in the ... the research provides a comprehensive view of the abnormal ... 50 genomic regions that are frequently gained or lost ...
Cached Biology News:'TRAP' preserves genetic properties of popular geranium 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3Genome study charts genetic landscape of lung cancer 2Genome study charts genetic landscape of lung cancer 3
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: